Regencell Bioscience Holdings Limited closed fiscal year 2026 with $14.7M in total assets, $1.4M in total liabilities and $13.3M in shareholder equity. Total assets rose 155.9% from the prior fiscal year. The table below carries 8 fiscal years, from 2019 to 2026, and the quarters Regencell Bioscience Holdings Limited has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
RGC Balance Sheet by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2620-F | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $14.7M+155.9% | $5.8M-31.8% | $8.4M-33.1% | $12.6M-30.0% | $18.0M+5197.6% | $340K-33.8% | $514K | N/A |
| Total Liabilities | $1.4M+54.2% | $895K+307.9% | $220K-65.3% | $632K-32.6% | $938K-78.4% | $4.3M+37.1% | $3.2M | N/A |
| Total Equity | $13.3M+174.7% | $4.9M-40.9% | $8.2M-31.7% | $12.0M-29.5% | $17.1Mn/m | -$4.0Mn/m | -$2.7Mn/m | -$1.8M |
RGC Balance Sheet by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q4'2620-F | Q4'2520-F | Q4'2420-F | Q4'2320-F | Q4'2220-F | Q4'2120-F | Q4'2020-F |
|---|---|---|---|---|---|---|---|
| Total Assets | $14.7M+155.9% | $5.8M-31.8% | $8.4M-33.1% | $12.6M-30.0% | $18.0M+5197.6% | $340K-33.8% | $514K |
| Total Liabilities | $1.4M+54.2% | $895K+307.9% | $220K-65.3% | $632K-32.6% | $938K-78.4% | $4.3M+37.1% | $3.2M |
| Total Equity | $13.3M+174.7% | $4.9M-40.9% | $8.2M-31.7% | $12.0M-29.5% | $17.1Mn/m | -$4.0Mn/m | -$2.7M |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Regencell Bioscience Holdings Limited financials
Frequently Asked Questions
Regencell Bioscience Holdings Limited closed fiscal year 2026 with $14.7M in total assets, $1.4M in total liabilities and $13.3M in shareholder equity.
Regencell Bioscience Holdings Limited (RGC) total assets rose by 155.9% year over year, from $5.8M to $14.7M in fiscal year 2026.
Regencell Bioscience Holdings Limited (RGC) reported $14.7M in total assets in Q4 2026. This represents an increase of 155.9% from the same quarter a year earlier.
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Regencell Bioscience Holdings Limited (RGC) reported on that line in every period on record.